Short Interest in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Drops By 14.6%

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) saw a significant decline in short interest in January. As of January 30th, there was short interest totaling 44,597 shares, a decline of 14.6% from the January 15th total of 52,250 shares. Based on an average daily trading volume, of 15,766 shares, the short-interest ratio is currently 2.8 days. Currently, 2.3% of the shares of the company are short sold. Currently, 2.3% of the shares of the company are short sold. Based on an average daily trading volume, of 15,766 shares, the short-interest ratio is currently 2.8 days.

Alaunos Therapeutics Stock Performance

NASDAQ:TCRT opened at $2.58 on Thursday. The stock has a 50 day moving average of $3.11 and a two-hundred day moving average of $2.88. Alaunos Therapeutics has a 12 month low of $1.31 and a 12 month high of $6.20. The firm has a market cap of $5.99 million, a P/E ratio of -1.12 and a beta of -1.19.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alaunos Therapeutics in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Hedge Funds Weigh In On Alaunos Therapeutics

A hedge fund recently raised its stake in Alaunos Therapeutics stock. Geode Capital Management LLC raised its holdings in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) by 25.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,736 shares of the company’s stock after acquiring an additional 3,945 shares during the period. Geode Capital Management LLC owned approximately 0.85% of Alaunos Therapeutics worth $64,000 at the end of the most recent quarter. 27.72% of the stock is owned by hedge funds and other institutional investors.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.